FCCC LOGO Faculty Publications
Abe O , Abe R , Enomoto K , Kikuchi K , Koyama H , Masuda H , Nomura Y , Sakai K , Sugimachi K , Tominaga T , Uchino J , Yoshida M , Haybittle JL , Davies C , Harvey VJ , Holdaway TM , Kay RG , Mason BH , Forbes JF , Wilcken N , Gnant M , Jakesz R , Ploner M , Yosef HMA , Focan C , Lobelle JP , Peek U , Oates GD , Powell J , Durand M , Mauriac L , Di Leo A , Dolci S , Piccart MJ , Masood MB , Parker D , Price JJ , Hupperets Psgj , Jackson S , Ragaz J , Berry D , Broadwater G , Cirrincione C , Muss H , Norton L , Weiss RB , Abu-Zahra HT , Portnoj SM , Baum M , Cuzick J , Houghton J , Riley D , Gordon NH , Davis HL , Beatrice A , Mihura J , Naja A , Lehingue Y , Romestaing P , Dubois JB , Delozier T , Mace-Lesec'h J , Rambert P , Andrysek O , Barkmanova J , Owen JR , Meier P , Howell A , Ribeiro GC , Swindell R , Alison R , Boreham J , Clarke M , Collins R , Darby S , Elphinstone P , Evans V , Godwin J , Gray R , Harwood C , Hicks C , James S , MacKinnon E , McGale! P , McHugh T , Mead G , Peto R , Wang Y , Albano J , de Oliveira CF , Gervasio H , Gordilho J , Johansen H , Mouridsen HT , Gelman RS , Harris JR , Henderson IC , Shapiro CL , Andersen KW , Axelsson CK , Blichert-Toft M , Moller S , Overgaard J , Overgaard M , Rose C , Cartensen B , Palshof T , Trampisch HJ , Dalesio O , de Vries EGE , Rodenhuis S , van Tinteren H , Comis RL , Davidson NE , Robert N , Sledge G , Tormey DC , Wood W , Cameron D , Chetty U , Forrest P , Jack W , Rossbach J , Klijn JGM , Treurniet-Donker AD , van Putten WLJ , Costa A , Veronesi U , Bartelink H , Duchateau L , Legrand C , Sylvester R , van der Hage JA , van de Velde CJH , Cunningham MP , Catalano R , Creech RH , Bonneterre J , Fargeot P , Fumoleau P , Kerbrat P , Namer M , Jonat W , Kaufmann M , Schumacher M , von Minckwitz G , Bastert G , Rauschecker H , Sauer R , Sauerbrei W , Schauer A , de Schryver A , Vakaet L , Belfiglio M , Nicolucci A , Pellegrini F , Sacco M , Valentini M , McArdle CS , Smith DC , Galligioni E , Bocc ardo F , Rubagotti A , Dent DM , Gudgeon CA , Hacking A , Erazo A , Medina JY , Izuo M , Morishita Y , Takei H , Fentiman IS , Hayward JL , Rubens RD , Skilton D , Graeff H , Janicke F , Meisner C , Scheurlen H , von Fournier D , Dafni U , Fountzilas G , Klefstrom P , Blomqvist C , Saarto T , Margreiter R , Asselain B , Salmon RJ , Vilcoq JR , Arriagada R , Hill C , Laplanche A , Le MG , Spielmann M , Bruzzi P , Montanaro E , Rosso R , Sertoli MR , Venturini M , Amadori D , Benraadt J , Kooi M , van de Velde AO , van Dongen JA , Vermorken JB , Castiglione M , Cavalli F , Coates A , Collins J , Forbes J , Gelber RD , Goldhirsch A , Lindtner J , Price KN , Rudenstam CM , Senn HJ , Bliss JM , Chilvers CED , Coombes RC , Hall E , Marty M , Borovik R , Brufman G , Hayat H , Robinson E , Wigler N , Bonadonna G , Camerini T , De Palo G , Del Vecchio M , Formelli F , Valagussa P , Martoni A , Pannuti F , Cocconi G , Colozza A , Camisa R , Aogi K , Takashima S , Ikeda T , Inokuchi K , Sawa K , Sonoo H , Korzeniowski S , Skolyszewski J , Ogawa M , Yamashita J , Bonte J , Christiaens R , Paridaens R , Van den Boegart W , Martin P , Romain S , Hakes T , Hudis CA , Wittes R , Giokas G , Kondylis D , Lissaios B , de la Huerta R , Sainz MG , Altemus R , Cowan K , Danforth D , Lichter A , Lippman M , O'Shaughnessy J , Pierce LJ , Steinberg S , Venzon D , Zujewski J , Paradiso A , De Lena M , Schittulli F , Myles JD , Pater JL , Pritchard KI , Anderson S , Bass G , Brown A , Bryant J , Costantino J , Dignam J , Fisher B , Redmond C , Wieand S , Wolmark N , Jackson IM , Palmer MK , Ingle JN , Suman VJ , Bengtsson NO , Jonsson H , Larsson LG , Lythgoe JP , Kissin M , Erikstein B , Hannisdal E , Jacobsen AB , Varhaug JE , Gundersen S , Hauer-Jensen M , Host H , Nissen-Meyer R , Blamey RW , Mitchell AK , Morgan DAL , Robertson JFR , Di Palma M , Mathe G , Misse! t JL , Clark RM , Levine M , Morimoto K , Takatsuka Y , Cross ley E , Harris A , Talbot D , Taylor M , di Blasio B , Ivanov V , Semiglazov V , Brockschmidt J , Cooper MR , Ueo H , Falkson CI , A'Hern R , Ashley S , Powles TJ , Smith IE , Yarnold JR , Gazet JC , Cocoran N , Deshpande N , di Martino L , Douglas P , Lindtner A , Notter G , Bryant AJS , Ewing GH , Firth LA , Krushen-Kosloski JL , Foster L , George WD , Stewart HJ , Stroner P , Malmstrom P , Moller TR , Ryden S , Tengrup I , Tennvall-Nittby L , Carstenssen J , Dufmats M , Hatschek T , Nordenskjold B , Soderberg M , Carpenter JT , Albain K , Crowley J , Green S , Martino S , Osborne CK , Ravdin PM , Glas U , Johansson U , Rutqvist LE , Singnomklao T , Wallgren A , Maibach R , Thurlimann B , Brenner H , Hercbergs A , Yoshimoto M , DeBoer G , Paterson AHG , Meakin JW , Panzarella T , Shan Y , Shao YF , Wang X , Zhao DB , Chen ZM , Pan HC , Bahi J , Reid M , Spittle M , Deutsch GP , Senanayake F , Kwong DLW , Bianco AR , Carlomagno C , De Laurentiis M , De Placido S , Buzdar AU , Smith T , Bergh J , Holmberg L , Liljegren G , Nilsson J , Seifert M , Sevelda P , Zielinsky CC , Buchanan RB , Cross M , Royle GT , Dunn JA , Hills RK , Lee M , Morrison JM , Spooner D , Litton A , Chlebowski RT , Caffier HGroup Author Ebctcg
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Lancet. 2005 May 14;365(9472) :1687-1717
Back to previous list
Abstract
Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
Notes
English Article